Click here to get full coverage on What Harrow (HROW)'s New US$50 Million Senior Notes Offering Means For Shareholders - Yahoo Finance UK

What Harrow (HROW)'s New US$50 Million Senior Notes Offering Means For Shareholders  Yahoo Finance UK

What Harrow (HROW)'s New US$50 Million Senior Notes Offering Means For Shareholders - Yahoo Finance UK

Click here to get full coverage on HROW Stock Price, Quote & Chart | HARROW INC (NASDAQ:HROW) - ChartMill

HROW Stock Price, Quote & Chart | HARROW INC (NASDAQ:HROW)  ChartMill

HROW Stock Price, Quote & Chart | HARROW INC (NASDAQ:HROW) - ChartMill

Click here to get full coverage on Harrow (NASDAQ: HROW) sells $50M of 8.625% notes due 2030 - Stock Titan

Harrow (NASDAQ: HROW) sells $50M of 8.625% notes due 2030  Stock Titan

Harrow (NASDAQ: HROW) sells $50M of 8.625% notes due 2030 - Stock Titan

Click here to get full coverage on Discipline and Rules-Based Execution in HROW Response - Stock Traders Daily

Discipline and Rules-Based Execution in HROW Response  Stock Traders Daily

Discipline and Rules-Based Execution in HROW Response - Stock Traders Daily

Click here to get full coverage on Opaleye Trims Harrow Stake After Earnings Miss While Debt Risk Rises - simplywall.st

Opaleye Trims Harrow Stake After Earnings Miss While Debt Risk Rises  simplywall.st

Opaleye Trims Harrow Stake After Earnings Miss While Debt Risk Rises - simplywall.st

Click here to get full coverage on Would You Still Hold Harrow Stock If It Fell Another 30%? - Trefis

Would You Still Hold Harrow Stock If It Fell Another 30%?  Trefis

Would You Still Hold Harrow Stock If It Fell Another 30%? - Trefis

Click here to get full coverage on Harrow Shares Collapse, Another Opportunity? (NASDAQ:HROW) - Seeking Alpha

Harrow Shares Collapse, Another Opportunity? (NASDAQ:HROW)  Seeking Alpha

Harrow Shares Collapse, Another Opportunity? (NASDAQ:HROW) - Seeking Alpha

Click here to get full coverage on Harrow (HROW) reports next week: Wall Street expects earnings growth - MSN

Harrow (HROW) reports next week: Wall Street expects earnings growth  MSN

Harrow (HROW) reports next week: Wall Street expects earnings growth - MSN

Click here to get full coverage on Vanguard disaggregates holdings — Harrow Inc (HROW) reports 0 shares - Stock Titan

Vanguard disaggregates holdings — Harrow Inc (HROW) reports 0 shares  Stock Titan

Vanguard disaggregates holdings — Harrow Inc (HROW) reports 0 shares - Stock Titan

Click here to get full coverage on HROW News | HARROW INC (NASDAQ:HROW) - ChartMill

HROW News | HARROW INC (NASDAQ:HROW)  ChartMill

HROW News | HARROW INC (NASDAQ:HROW) - ChartMill

Click here to get full coverage on How Investors May Respond To Harrow (HROW) Issuing US$50M In 8.625% Senior Notes For Growth - simplywall.st

How Investors May Respond To Harrow (HROW) Issuing US$50M In 8.625% Senior Notes For Growth  simplywall.st

How Investors May Respond To Harrow (HROW) Issuing US$50M In 8.625% Senior Notes For Growth - simplywall.st

Click here to get full coverage on Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market (NASDAQ:HROW) - Seeking Alpha

Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market (NASDAQ:HROW)  Seeking Alpha

Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market (NASDAQ:HROW) - Seeking Alpha

Click here to get full coverage on Harrow (HROW) Misses Q4 Earnings Estimates - Yahoo Finance

Harrow (HROW) Misses Q4 Earnings Estimates  Yahoo Finance

Harrow (HROW) Misses Q4 Earnings Estimates - Yahoo Finance

Click here to get full coverage on HARROW INC (NASDAQ:HROW): A GARP Stock with Strong Growth at a Reasonable Price - ChartMill

HARROW INC (NASDAQ:HROW): A GARP Stock with Strong Growth at a Reasonable Price  ChartMill

HARROW INC (NASDAQ:HROW): A GARP Stock with Strong Growth at a Reasonable Price - ChartMill

Click here to get full coverage on Harrow (NASDAQ: HROW) adds $50M to 8.625% 2030 senior notes - Stock Titan

Harrow (NASDAQ: HROW) adds $50M to 8.625% 2030 senior notes  Stock Titan

Harrow (NASDAQ: HROW) adds $50M to 8.625% 2030 senior notes - Stock Titan

Click here to get full coverage on A Look At Harrow’s Valuation After Recent Share Price Pullback - simplywall.st

A Look At Harrow’s Valuation After Recent Share Price Pullback  simplywall.st

A Look At Harrow’s Valuation After Recent Share Price Pullback - simplywall.st

Click here to get full coverage on Eye drug studies on dry eye and cataract surgery headed to DC stage - Stock Titan

Eye drug studies on dry eye and cataract surgery headed to DC stage  Stock Titan

Eye drug studies on dry eye and cataract surgery headed to DC stage - Stock Titan

Click here to get full coverage on Eye drug maker Harrow targets up to $365M in 2026 revenue - Stock Titan

Eye drug maker Harrow targets up to $365M in 2026 revenue  Stock Titan

Eye drug maker Harrow targets up to $365M in 2026 revenue - Stock Titan

Click here to get full coverage on Here's What Could Help Harrow (HROW) Maintain Its Recent Price Strength - Yahoo Finance

Here's What Could Help Harrow (HROW) Maintain Its Recent Price Strength  Yahoo Finance

Here's What Could Help Harrow (HROW) Maintain Its Recent Price Strength - Yahoo Finance

Click here to get full coverage on Harrow (HROW) -28%: 2026 Guidance Disappoints Market - Trefis

Harrow (HROW) -28%: 2026 Guidance Disappoints Market  Trefis

Harrow (HROW) -28%: 2026 Guidance Disappoints Market - Trefis

Click here to get full coverage on Harrow: The Post Earnings Drop Exposes The Cost Of Growth (Rating Downgrade) (NASDAQ:HROW) - Seeking Alpha

Harrow: The Post Earnings Drop Exposes The Cost Of Growth (Rating Downgrade) (NASDAQ:HROW)  Seeking Alpha

Harrow: The Post Earnings Drop Exposes The Cost Of Growth (Rating Downgrade) (NASDAQ:HROW) - Seeking Alpha

Click here to get full coverage on Harrow (HROW) Is Up After Q3 Profit Turnaround and Revenue Growth Are Reported – What's Changed - Yahoo Finance

Harrow (HROW) Is Up After Q3 Profit Turnaround and Revenue Growth Are Reported – What's Changed  Yahoo Finance

Harrow (HROW) Is Up After Q3 Profit Turnaround and Revenue Growth Are Reported – What's Changed - Yahoo Finance

Click here to get full coverage on Harrow (NASDAQ: HROW) plans $50M add-on 8.625% 2030 note issue - Stock Titan

Harrow (NASDAQ: HROW) plans $50M add-on 8.625% 2030 note issue  Stock Titan

Harrow (NASDAQ: HROW) plans $50M add-on 8.625% 2030 note issue - Stock Titan

Click here to get full coverage on Breakeven Is Near for Harrow, Inc. (NASDAQ:HROW) - Yahoo Finance

Breakeven Is Near for Harrow, Inc. (NASDAQ:HROW)  Yahoo Finance

Breakeven Is Near for Harrow, Inc. (NASDAQ:HROW) - Yahoo Finance

Click here to get full coverage on Harrow, Inc. (HROW): A Bull Case Theory - Yahoo Finance

Harrow, Inc. (HROW): A Bull Case Theory  Yahoo Finance

Harrow, Inc. (HROW): A Bull Case Theory - Yahoo Finance

Click here to get full coverage on Why Harrow (HROW) Is Down 6.5% After Raising 2026 Guidance And Advancing TRIESENCE To Phase 3 - simplywall.st

Why Harrow (HROW) Is Down 6.5% After Raising 2026 Guidance And Advancing TRIESENCE To Phase 3  simplywall.st

Why Harrow (HROW) Is Down 6.5% After Raising 2026 Guidance And Advancing TRIESENCE To Phase 3 - simplywall.st

Click here to get full coverage on Assessing Harrow (HROW) Valuation After Strong Revenue Growth And TRIESENCE Phase 3 Progress - Sahm

Assessing Harrow (HROW) Valuation After Strong Revenue Growth And TRIESENCE Phase 3 Progress  Sahm

Assessing Harrow (HROW) Valuation After Strong Revenue Growth And TRIESENCE Phase 3 Progress - Sahm

Click here to get full coverage on Daniel Kaufman holds 1.878M Harrow shares (HROW) — 5.04% reported - Stock Titan

Daniel Kaufman holds 1.878M Harrow shares (HROW) — 5.04% reported  Stock Titan

Daniel Kaufman holds 1.878M Harrow shares (HROW) — 5.04% reported - Stock Titan

Click here to get full coverage on Harrow (NASDAQ:HROW) Shares Gap Down After Earnings Miss - MarketBeat

Harrow (NASDAQ:HROW) Shares Gap Down After Earnings Miss  MarketBeat

Harrow (NASDAQ:HROW) Shares Gap Down After Earnings Miss - MarketBeat

Click here to get full coverage on Harrow Raises $50 Million Via Additional 8.625% Senior Notes Due 2030; Signs Purchase Agreement and Indenture - TradingView

Harrow Raises $50 Million Via Additional 8.625% Senior Notes Due 2030; Signs Purchase Agreement and Indenture  TradingView

Harrow Raises $50 Million Via Additional 8.625% Senior Notes Due 2030; Signs Purchase Agreement and Indenture - TradingView

Click here to get full coverage on A Look At Harrow’s (HROW) Valuation As 2025 Guidance Is Reaffirmed And Regulatory Issues Clear - Yahoo Finance

A Look At Harrow’s (HROW) Valuation As 2025 Guidance Is Reaffirmed And Regulatory Issues Clear  Yahoo Finance

A Look At Harrow’s (HROW) Valuation As 2025 Guidance Is Reaffirmed And Regulatory Issues Clear - Yahoo Finance

Click here to get full coverage on HROW SEC Filings - Harrow Health Inc 10-K, 10-Q, 8-K Forms - Stock Titan

HROW SEC Filings - Harrow Health Inc 10-K, 10-Q, 8-K Forms  Stock Titan

HROW SEC Filings - Harrow Health Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Click here to get full coverage on Harrow Stock (-8.3%): Major Holder Sale Near Highs Sparks Distribution - Trefis

Harrow Stock (-8.3%): Major Holder Sale Near Highs Sparks Distribution  Trefis

Harrow Stock (-8.3%): Major Holder Sale Near Highs Sparks Distribution - Trefis

Click here to get full coverage on Harrow (NASDAQ: HROW) furnishes March 2026 corporate investor presentation - Stock Titan

Harrow (NASDAQ: HROW) furnishes March 2026 corporate investor presentation  Stock Titan

Harrow (NASDAQ: HROW) furnishes March 2026 corporate investor presentation - Stock Titan

Click here to get full coverage on Eye drug TRIESENCE moves into Phase 3 test to ease cataract surgery recovery - Stock Titan

Eye drug TRIESENCE moves into Phase 3 test to ease cataract surgery recovery  Stock Titan

Eye drug TRIESENCE moves into Phase 3 test to ease cataract surgery recovery - Stock Titan

Click here to get full coverage on Harrow, Inc. (NASDAQ:HROW) Looks Just Right With A 27% Price Jump - simplywall.st

Harrow, Inc. (NASDAQ:HROW) Looks Just Right With A 27% Price Jump  simplywall.st

Harrow, Inc. (NASDAQ:HROW) Looks Just Right With A 27% Price Jump - simplywall.st

Click here to get full coverage on How CVS Elevating Vevye To Tier 1 Coverage At Harrow (HROW) Has Changed Its Investment Story - Yahoo Finance

How CVS Elevating Vevye To Tier 1 Coverage At Harrow (HROW) Has Changed Its Investment Story  Yahoo Finance

How CVS Elevating Vevye To Tier 1 Coverage At Harrow (HROW) Has Changed Its Investment Story - Yahoo Finance

Click here to get full coverage on Harrow Inc (HROW) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic Growth Plans - Yahoo Finance

Harrow Inc (HROW) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic Growth Plans  Yahoo Finance

Harrow Inc (HROW) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic Growth Plans - Yahoo Finance

Click here to get full coverage on A Fresh Look at Harrow (HROW) Valuation Following Recent Revenue Growth and Long-Term Performance - Yahoo Finance

A Fresh Look at Harrow (HROW) Valuation Following Recent Revenue Growth and Long-Term Performance  Yahoo Finance

A Fresh Look at Harrow (HROW) Valuation Following Recent Revenue Growth and Long-Term Performance - Yahoo Finance

Click here to get full coverage on Opaleye trims Harrow stake as entities sell 198K shares (HROW) - Stock Titan

Opaleye trims Harrow stake as entities sell 198K shares (HROW)  Stock Titan

Opaleye trims Harrow stake as entities sell 198K shares (HROW) - Stock Titan

Click here to get full coverage on Harrow drops California compounding business over rising regulatory costs - Stock Titan

Harrow drops California compounding business over rising regulatory costs  Stock Titan

Harrow drops California compounding business over rising regulatory costs - Stock Titan

Click here to get full coverage on Could Harrow’s (HROW) New Pricing Program Redefine Its Patient Access Advantage? - Yahoo Finance

Could Harrow’s (HROW) New Pricing Program Redefine Its Patient Access Advantage?  Yahoo Finance

Could Harrow’s (HROW) New Pricing Program Redefine Its Patient Access Advantage? - Yahoo Finance

Click here to get full coverage on Harrow: Flirting With Missing 2025 Revised Guidance (NASDAQ:HROW) - Seeking Alpha

Harrow: Flirting With Missing 2025 Revised Guidance (NASDAQ:HROW)  Seeking Alpha

Harrow: Flirting With Missing 2025 Revised Guidance (NASDAQ:HROW) - Seeking Alpha

Click here to get full coverage on Analyst Downgrade: How much upside does HROW have - 2026 Outlook & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn

Analyst Downgrade: How much upside does HROW have - 2026 Outlook & Risk Adjusted Buy/Sell Alerts  baoquankhu1.vn

Analyst Downgrade: How much upside does HROW have - 2026 Outlook & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn

Click here to get full coverage on Harrow, Inc. (NASDAQ:HROW) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Harrow, Inc. (NASDAQ:HROW) Receives Consensus Recommendation of "Moderate Buy" from Analysts  MarketBeat

Harrow, Inc. (NASDAQ:HROW) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Click here to get full coverage on Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating, Announces Target Price $59 - 富途牛牛

Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating, Announces Target Price $59  富途牛牛

Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating, Announces Target Price $59 - 富途牛牛

Click here to get full coverage on Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential (NASDAQ:HROW) - Seeking Alpha

Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential (NASDAQ:HROW)  Seeking Alpha

Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential (NASDAQ:HROW) - Seeking Alpha

Click here to get full coverage on Harrow (NASDAQ: HROW) lifts 2025 revenue 36% and sets 2026 outlook - Stock Titan

Harrow (NASDAQ: HROW) lifts 2025 revenue 36% and sets 2026 outlook  Stock Titan

Harrow (NASDAQ: HROW) lifts 2025 revenue 36% and sets 2026 outlook - Stock Titan

Click here to get full coverage on Core Biotech Trades For Monday: Selling GERN & HROW. New Position In RARE, Adding To DERM (NASDAQ:RARE) - Seeking Alpha

Core Biotech Trades For Monday: Selling GERN & HROW. New Position In RARE, Adding To DERM (NASDAQ:RARE)  Seeking Alpha

Core Biotech Trades For Monday: Selling GERN & HROW. New Position In RARE, Adding To DERM (NASDAQ:RARE) - Seeking Alpha

Click here to get full coverage on Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release  Yahoo Finance

Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Click here to get full coverage on Harrow Inc (HROW) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance

Harrow Inc (HROW) Q2 2025: Everything You Need To Know Ahead Of Earnings  Yahoo Finance

Harrow Inc (HROW) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance

Click here to get full coverage on Opaleye-managed account sells Harrow (HROW) shares at $54.18 in Form 4 - Stock Titan

Opaleye-managed account sells Harrow (HROW) shares at $54.18 in Form 4  Stock Titan

Opaleye-managed account sells Harrow (HROW) shares at $54.18 in Form 4 - Stock Titan

Click here to get full coverage on $HROW stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

$HROW stock is down 8% today. Here's what we see in our data.  Quiver Quantitative

$HROW stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Harrow (NASDAQ:HROW) Given Buy Rating at BTIG Research - MarketBeat

Harrow (NASDAQ:HROW) Given Buy Rating at BTIG Research  MarketBeat

Harrow (NASDAQ:HROW) Given Buy Rating at BTIG Research - MarketBeat

Click here to get full coverage on Harrow’s Leerink healthcare talk will stream live on March 10 - Stock Titan

Harrow’s Leerink healthcare talk will stream live on March 10  Stock Titan

Harrow’s Leerink healthcare talk will stream live on March 10 - Stock Titan

Click here to get full coverage on Harrow, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:HROW) 2026-03-06 - Seeking Alpha

Harrow, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:HROW) 2026-03-06  Seeking Alpha

Harrow, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:HROW) 2026-03-06 - Seeking Alpha

Click here to get full coverage on Cantor Fitzgerald Lowers Harrow (NASDAQ:HROW) Price Target to $91.00 - MarketBeat

Cantor Fitzgerald Lowers Harrow (NASDAQ:HROW) Price Target to $91.00  MarketBeat

Cantor Fitzgerald Lowers Harrow (NASDAQ:HROW) Price Target to $91.00 - MarketBeat

Click here to get full coverage on Harrow Stock (+9.7%): Commercial Expansion Ignites Institutional Buying - Trefis

Harrow Stock (+9.7%): Commercial Expansion Ignites Institutional Buying  Trefis

Harrow Stock (+9.7%): Commercial Expansion Ignites Institutional Buying - Trefis

Click here to get full coverage on Behavioral Patterns of HROW and Institutional Flows - Stock Traders Daily

Behavioral Patterns of HROW and Institutional Flows  Stock Traders Daily

Behavioral Patterns of HROW and Institutional Flows - Stock Traders Daily

Click here to get full coverage on HROW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

HROW Financials: Income Statement, Balance Sheet & Cash Flow  Stock Titan

HROW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Click here to get full coverage on Nomura Downgrades Harrow Health (HROW) to Neutral on March 18, 2026 - Meyka

Nomura Downgrades Harrow Health (HROW) to Neutral on March 18, 2026  Meyka

Nomura Downgrades Harrow Health (HROW) to Neutral on March 18, 2026 - Meyka

Click here to get full coverage on Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS (NASDAQ:HROW) - Seeking Alpha

Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS (NASDAQ:HROW)  Seeking Alpha

Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS (NASDAQ:HROW) - Seeking Alpha

Click here to get full coverage on Harrow, Inc. (HROW) Emerges as Eye Care Powerhouse With Biosimilars to Lucentis and Eylea - Yahoo Finance

Harrow, Inc. (HROW) Emerges as Eye Care Powerhouse With Biosimilars to Lucentis and Eylea  Yahoo Finance

Harrow, Inc. (HROW) Emerges as Eye Care Powerhouse With Biosimilars to Lucentis and Eylea - Yahoo Finance

Click here to get full coverage on Nomura Downgrades Harrow Health, Inc. (HROW) to Neutral March 18, 2026 - Meyka

Nomura Downgrades Harrow Health, Inc. (HROW) to Neutral March 18, 2026  Meyka

Nomura Downgrades Harrow Health, Inc. (HROW) to Neutral March 18, 2026 - Meyka

Click here to get full coverage on Eye Care Stock Sees New Path After Guidance - Investor's Business Daily

Eye Care Stock Sees New Path After Guidance  Investor's Business Daily

Eye Care Stock Sees New Path After Guidance - Investor's Business Daily

Click here to get full coverage on Frank Mullery named CEO; Bridseida Cruz named Head of Quality at ImprimisRx, Harrow subsidiary - Stock Titan

Frank Mullery named CEO; Bridseida Cruz named Head of Quality at ImprimisRx, Harrow subsidiary  Stock Titan

Frank Mullery named CEO; Bridseida Cruz named Head of Quality at ImprimisRx, Harrow subsidiary - Stock Titan

Click here to get full coverage on Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update (NASDAQ:HROW) - Seeking Alpha

Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update (NASDAQ:HROW)  Seeking Alpha

HROW

Price Chart

Key Statistics

Technicals

About HROW

Latest News

What Harrow (HROW)'s New US$50 Million Senior Notes Offering Means For Shareholders - Yahoo Finance UK

HROW Stock Price, Quote & Chart | HARROW INC (NASDAQ:HROW) - ChartMill

Harrow (NASDAQ: HROW) sells $50M of 8.625% notes due 2030 - Stock Titan

Advanced Charts

Top Gainers

Top Losers